ACUTE TOXICITY OF DIFFERENT SIZES OF SILVER NANOPARTICLES INTRAPERITONALLY INJECTED IN BALB/C MICE USING TWO TOXICOLOGICAL METHODS

  • Elham A. Elkhawass Zoology Department, Faculty of Science, Suez Canal University, Ismailia, Egypt
  • Mahmoud E. Mohallal Zoology Department, Faculty of Science, Suez Canal University, Ismailia, Egypt
  • Maha F. M. Soliman Zoology Department, Faculty of Science, Suez Canal University, Ismailia, Egypt

Abstract

Objective: This study aimed to evaluate the acute toxicity of intraperitoneally administrated silver nanoparticles (AgNPs) with different particle sizes in BALB/c mice.

Methods: Citrate-capped AgNPs were prepared by citrate reduction method and isolated into small particles (average size 20 nm) and large particles (average size 50 nm). The median lethal dose (LD50) of 20 nm and 50 nm AgNPs was estimated using two toxicological methods, classical Dixon's up-and-down method and AOT425statPgm method for up-and-down procedure.

Results: The LD50 was evaluated at the dosage level of 169 and 213.8 mg/kg, respectively for 20 nm AgNPs and at the dosage level of 354 and 391.5 mg/kg, respectively for 50 nm AgNPs. The results showed that LD50 obtained by the AOT425statPgm method was in accord with that of the Dixon's method and no significant differences between them (P = 0.06). The size 20 nm AgNPs were more toxic than the size 50 nm AgNPs. The behavioural responses and deviations were dose dependent, increasing by increasing the dose. The anatomical examinations showed that AgNPs were mainly accumulated in liver and spleen of dosed mice.

Conclusion: The results suggested that the AOT425statPgm method was an efficient tool and a good alternative method for use in future acute toxicity studies.

 

Keywords: Silver nanoparticles, Median lethal dose, LD50, Acute toxicity, Mice

Downloads

Download data is not yet available.

References

1. Durán N, Guterres SS, Oswaldo Alves L. Nanotoxicology: materials, methodologies, and assessments. New York: Springer; 2014.
2. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007;18:26-30.
3. Devaraj P, Aarti C, Kumari P. Synthesis and characterization of silver nanoparticles using tabernaemontana divaricata and its cytotoxic activity against MCF-7 cell line. Int J Pharm Pharm Sci 2014;6:86-90.
4. Donaldson K, Borm P. Particle Toxicology: CRC Press; 2007.
5. Donaldson K, Stone V, Clouter A, Renwick L, MacNee W. Ultrafine particles. Occup Environ Med 2001;58:211-6.
6. Priyaragini S, Sathishkumar SR, Bhaskararao KV. Biosynthesis of silver nanoparticles using actinobacteria and evaluating its antimicrobial and cytotoxicity activity. Int J Pharm Pharm Sci 2013;5(Suppl 2):709-12.
7. Auffan M, Rose J, Proux O, Borschneck D, Masion A, Chaurand P, et al. Enhanced adsorption of arsenic onto maghemites nanoparticles: as(iii) as a probe of the surface structure and heterogeneity. Langmuir 2008;24:3215-22.
8. Ji ZQ, Sun H, Wang H, Xie Q, Liu Y, Wang Z. Biodistribution and tumor uptake of C60(OH)x in mice. J Nanopart Res 2006;8:53-63.
9. Nemmar A, Hoet PH, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, et al. Passage of inhaled particles into the blood circulation in humans. Circulation 2002;105:411-4.
10. Dugal S, Chakraborty S. Biogenic synthesis of nanosilver and its antibacterial effect against resistant Gram negative pathogens. Int J Pharm Pharm Sci 2013;5:498-501.
11. Nano Health Solutions, (2010). http://www.fulvic.org/ html/nano_silver.html Roduner E. Size matters: why nanomaterials are different. Chem Soc Revs 2006;35;583-92.
12. Monteiro DR, Gorup LF, Takamiya AS, Ruvollo-Filho AC, de Camargo ER, et al. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medicaldevices containing silver. Int J Antimicrob 2009;34:103-10.
13. Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett 2008;176:1-12.
14. Salata O. Application of nanoparticles in biology and medicine. J Nanobiotechnol 2004;2:1-6.
15. Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 1999;27:344-50.
16. Chen J, Choe MK, Chen S, Zhang S. Community environment and HIV/AIDS-related stigma in China. AIDS Educ Prev 2005;17:1-11.
17. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol 2005;3:6.
18. Asharani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC Cell Biol 2009;10:65.
19. Ernest V, George Priya Doss C, Muthiah A, Mukherjee A, Chandrasekaran N. Genotoxicity assessment of low concentration AgNPs to human peripheral blood lymphocytes. Int J Pharm Pharm Sci 2013;5:377-81.
20. Klaine SJ, Alvarez PJJ, Batley, GE. Nanomaterials in the environment: behaviour, fate, bioavailability and effects. Environ Toxicol Chem 2008;27:1825-51.
21. Nowack B, Krug HF, Height M. 120 Years of nanosilver history: Implications for policy makers. Environ Sci Technol 2011;45:1177-83.
22. Xiu Z, Zhang Q, Puppala HL. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett 2012;12:4271-5.
23. Burrell RE. A scientific perspective on the use of topical silver preparations. Ostomy Wound Manag 2003;49:19-24.
24. Wijnhoven SWP, Peijnenburg, WJGM, Herberts CA. Nano-silver-a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicol 2009;3:109-38.
25. Chen D, Xi T, Bai J, Wang J. Nanosilver subchronic toxicity and silver distribution in different rat tissues. J Clin Rehabil Tissue Engin Res 2009;13:3181-3.
26. Ji JH, Jung JH, Kim SS, Yoon JU, Park JD, Choi BS, et al. Twentyeight-day inhalation toxicity study of silver nanoparticles in Sprague–Dawley rats. Inhal Toxicol 2007;19:857-71.
27. Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, et al. Twentyeight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague–Dawley rats. Inhal Toxicol 2008;20:575-83.
28. Kim WY, Kim J, Park JD, Ryu HY, Yu IJ. Histological study of gender differences in accumulation of silver nanoparticles in kidneys of fischer 344 rats. J Toxicol Environ Health Part A 2009;72:1279-84.
29. Loeschner K, Hadrup N, Qvortrup K, Larsen A, Gao X. Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. Part Fibre Toxicol 2011;8:8-18.
30. Park EJ, Choi K, Park K. Induction of inflammatory responses and gene expression by intratracheal instillation of silver nanoparticles in mice. Arch Pharm Res 2011;34:299-307.
31. Takenaka S, Karg E, Roth C, Schulz H, Ziesenis A, Heinzmann U, Schramel P, Heyder J. Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats. Environ Health Perspect 2001;109:547-51.
32. Tang J, Xiong L, Wang S, Wang J, Liu L, Li J, Yuan F, et al. Distribution, translocation and accumulation of silver nanoparticles in rats. J Nanosci Nanotechnol 2009;9:4924-32.
33. Schmaehl D, Steinhoff D. Studies on cancer induction with colloidal silver and gold solutions in rats. Z Krebsforsch 1960;63:586-91.
34. Sileikaite A, Prosycevas I, Puiso J, Juraitis A, Guobiene A. Analysis of silver nanoparticles produced by chemical reduction of silver salt solution. Mater Sci 2006;12:287-91.
35. Rasband WS, ImageJ US. National Institutes of Health, Bethesda, Maryland: USA; 1997.
36. Dixon WJ. Efficient analysis of experimental observations. Ann Rev Pharmacol Toxicol 1980;20:441-62.
37. Dixon WJ. The up-and-down method for small samples. J Amer Statist Assoc 1965;60:967-78.
38. OECD [Organisation for Economic Co-operation and Development]. Acute oral toxicity-modified up and down procedure, No. 425. Paris: OECD; 1998.
39. Kim TH, Kim M, Park HS, Shin US, Gong MS, Kim HW. Size-dependent cellular toxicity of silver nanoparticles. J Biomed Mater Res A 2012;100:1033-43.
40. Ivask A, Kurvet I, Kasemets K, Blinova I, Aruoja V. Size-Dependent toxicity of silver nanoparticles to bacteria, yeast, algae, Crustaceans and mammalian cells in vitro. PLoS ONE 2014;9:102-8.
41. Mulvaney P. Surface plasmon spectroscopy of nanosized metal particles. Langmuir 1996;12:788-800.
42. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium escherichia coli. Ppl Environ Microbiol 2007;73:1712–20.
43. Mie G. Contributions to the optics of turbid media, especially colloidal metal solutions. Ann Phys 1908;25:377-445.
44. Link S, El-Sayed MA. Spectral properties and relaxation dynamics of surface plasmon electronic oscillations in gold and silver nanodots and nanorods. J Phys Chem B 1999;103:8410-26.
45. Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 2011;50:600-13.
46. OECD. Harmonized Integrated Hazard Classification System for Human Health and Environmental Effects of Chemical Substances, as endorsed by the 32nd Joint Meeting of the Chemicals, Pesticides and Biotechnology; 2001.
47. GHS: Globally Harmonized System of Classification and Labelling of Chemicals, United Nations, 1st Revised Edition; 2005.
48. Liu W, Wu Y, Wang C, Li HC, Wang T, Liao CY, et al. Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicol 2010;4:319-30.
Statistics
717 Views | 1716 Downloads
How to Cite
Elkhawass, E. A., M. E. Mohallal, and M. F. M. Soliman. “ACUTE TOXICITY OF DIFFERENT SIZES OF SILVER NANOPARTICLES INTRAPERITONALLY INJECTED IN BALB/C MICE USING TWO TOXICOLOGICAL METHODS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 2, Dec. 2014, pp. 94-99, https://innovareacademics.in/journals/index.php/ijpps/article/view/3776.
Section
Original Article(s)